vs
Assertio Holdings, Inc.（ASRT）与Axil Brands, Inc.（AXIL）财务数据对比。点击上方公司名可切换其他公司
Assertio Holdings, Inc.的季度营收约是Axil Brands, Inc.的1.7倍（$13.5M vs $8.1M），Axil Brands, Inc.同比增速更快（5.2% vs -57.9%），过去两年Axil Brands, Inc.的营收复合增速更高（12.1% vs -35.4%）
Assertio Therapeutics是一家美国专业制药企业，主要聚焦神经病学、疼痛以及中枢神经系统疾病领域的产品销售与推广。公司前身Depomed成立于1995年，总部位于加利福尼亚州纽瓦克，拥有多款获美国FDA批准的产品，目前在纳斯达克上市。
Axil Brands是一家总部位于美国的专业消费电子企业，主营高端听力防护设备、音频增强装置及个性化音频配件，旗下产品涵盖定制耳塞、运动蓝牙耳机等，面向全球普通消费者及专业作业群体销售。
ASRT vs AXIL — 直观对比
营收规模更大
ASRT
是对方的1.7倍
$8.1M
营收增速更快
AXIL
高出63.1%
-57.9%
两年增速更快
AXIL
近两年复合增速
-35.4%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $13.5M | $8.1M |
| 净利润 | — | $704.9K |
| 毛利率 | — | 68.1% |
| 营业利润率 | -86.7% | 11.1% |
| 净利率 | — | 8.7% |
| 营收同比 | -57.9% | 5.2% |
| 净利润同比 | — | 11.2% |
| 每股收益（稀释后） | $-4.54 | $0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASRTAXIL
| Q4 25 | $13.5M | $8.1M | ||
| Q3 25 | $49.5M | $6.9M | ||
| Q2 25 | $29.2M | $5.8M | ||
| Q1 25 | $26.5M | $6.9M | ||
| Q4 24 | $32.2M | $7.7M | ||
| Q3 24 | $29.2M | $5.9M | ||
| Q2 24 | $31.1M | $6.5M | ||
| Q1 24 | $32.4M | $6.5M |
净利润ASRTAXIL
| Q4 25 | — | $704.9K | ||
| Q3 25 | $11.4M | $334.3K | ||
| Q2 25 | $-16.4M | $-245.6K | ||
| Q1 25 | $-13.5M | $576.7K | ||
| Q4 24 | — | $633.7K | ||
| Q3 24 | $-2.9M | $-109.8K | ||
| Q2 24 | $-3.7M | $49.5K | ||
| Q1 24 | $-4.5M | $781.1K |
毛利率ASRTAXIL
| Q4 25 | — | 68.1% | ||
| Q3 25 | — | 67.6% | ||
| Q2 25 | — | 70.0% | ||
| Q1 25 | — | 71.7% | ||
| Q4 24 | — | 71.1% | ||
| Q3 24 | — | 71.0% | ||
| Q2 24 | — | 71.5% | ||
| Q1 24 | — | 71.5% |
营业利润率ASRTAXIL
| Q4 25 | -86.7% | 11.1% | ||
| Q3 25 | 23.2% | 6.0% | ||
| Q2 25 | -27.5% | 0.8% | ||
| Q1 25 | -50.0% | 8.4% | ||
| Q4 24 | -41.9% | 8.7% | ||
| Q3 24 | -10.4% | -2.4% | ||
| Q2 24 | -11.6% | 2.6% | ||
| Q1 24 | -13.4% | -1.6% |
净利率ASRTAXIL
| Q4 25 | — | 8.7% | ||
| Q3 25 | 23.1% | 4.9% | ||
| Q2 25 | -56.0% | -4.3% | ||
| Q1 25 | -51.1% | 8.3% | ||
| Q4 24 | — | 8.2% | ||
| Q3 24 | -10.0% | -1.9% | ||
| Q2 24 | -11.8% | 0.8% | ||
| Q1 24 | -13.9% | 12.1% |
每股收益（稀释后）ASRTAXIL
| Q4 25 | $-4.54 | $0.09 | ||
| Q3 25 | $0.11 | $0.04 | ||
| Q2 25 | $-0.17 | $-0.03 | ||
| Q1 25 | $-0.14 | $0.07 | ||
| Q4 24 | $-3.28 | $0.08 | ||
| Q3 24 | $-0.03 | $-0.02 | ||
| Q2 24 | $-0.04 | $0.11 | ||
| Q1 24 | $-0.05 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $63.4M | $5.0M |
| 总债务越低越好 | — | $138.3K |
| 股东权益账面价值 | $94.0M | $11.1M |
| 总资产 | $267.0M | $16.2M |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资ASRTAXIL
| Q4 25 | $63.4M | $5.0M | ||
| Q3 25 | $93.4M | $4.1M | ||
| Q2 25 | $98.2M | $4.8M | ||
| Q1 25 | $87.3M | $4.7M | ||
| Q4 24 | $100.1M | $5.2M | ||
| Q3 24 | $88.6M | $4.1M | ||
| Q2 24 | $88.4M | $3.3M | ||
| Q1 24 | $80.7M | $4.9M |
总债务ASRTAXIL
| Q4 25 | — | $138.3K | ||
| Q3 25 | — | $139.2K | ||
| Q2 25 | — | $140.2K | ||
| Q1 25 | — | $141.0K | ||
| Q4 24 | — | $143.3K | ||
| Q3 24 | — | $144.3K | ||
| Q2 24 | — | $146.6K | ||
| Q1 24 | $38.6M | — |
股东权益ASRTAXIL
| Q4 25 | $94.0M | $11.1M | ||
| Q3 25 | $105.8M | $10.2M | ||
| Q2 25 | $93.3M | $9.7M | ||
| Q1 25 | $108.5M | $9.7M | ||
| Q4 24 | $121.1M | $8.8M | ||
| Q3 24 | $130.5M | $7.9M | ||
| Q2 24 | $132.2M | $7.7M | ||
| Q1 24 | $134.5M | $8.8M |
总资产ASRTAXIL
| Q4 25 | $267.0M | $16.2M | ||
| Q3 25 | $319.8M | $15.4M | ||
| Q2 25 | $273.8M | $12.9M | ||
| Q1 25 | $286.4M | $13.0M | ||
| Q4 24 | $284.7M | $13.7M | ||
| Q3 24 | $276.0M | $11.4M | ||
| Q2 24 | $279.4M | $11.0M | ||
| Q1 24 | $282.0M | $12.7M |
负债/权益比ASRTAXIL
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.01× | ||
| Q1 25 | — | 0.01× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.02× | ||
| Q2 24 | — | 0.02× | ||
| Q1 24 | 0.29× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-30.0M | $934.8K |
| 自由现金流经营现金流 - 资本支出 | — | $906.4K |
| 自由现金流率自由现金流/营收 | — | 11.1% |
| 资本支出强度资本支出/营收 | — | 0.3% |
| 现金转化率经营现金流/净利润 | — | 1.33× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ASRTAXIL
| Q4 25 | $-30.0M | $934.8K | ||
| Q3 25 | $-4.8M | $-739.2K | ||
| Q2 25 | $19.1M | $194.4K | ||
| Q1 25 | $-12.5M | $-169.9K | ||
| Q4 24 | $11.5M | $1.0M | ||
| Q3 24 | $-35.0K | $897.3K | ||
| Q2 24 | $7.4M | $-336.6K | ||
| Q1 24 | $7.5M | $-912.8K |
自由现金流ASRTAXIL
| Q4 25 | — | $906.4K | ||
| Q3 25 | — | $-747.6K | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-258.2K | ||
| Q4 24 | — | $941.1K | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-394.9K | ||
| Q1 24 | — | $-922.1K |
自由现金流率ASRTAXIL
| Q4 25 | — | 11.1% | ||
| Q3 25 | — | -10.9% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -3.7% | ||
| Q4 24 | — | 12.2% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -6.1% | ||
| Q1 24 | — | -14.3% |
资本支出强度ASRTAXIL
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.3% | ||
| Q4 24 | — | 0.9% | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | — | 0.9% | ||
| Q1 24 | — | 0.1% |
现金转化率ASRTAXIL
| Q4 25 | — | 1.33× | ||
| Q3 25 | -0.42× | -2.21× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -0.29× | ||
| Q4 24 | — | 1.59× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -6.80× | ||
| Q1 24 | — | -1.17× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASRT
| Products | $12.8M | 95% |
| Other | $719.0K | 5% |
AXIL
| Hearing Enhancement And Protection | $7.8M | 95% |
| Other | $378.9K | 5% |
